Acquired Hemophilia Treatment Global Market Report 2025
상품코드:1824556
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
후천성 혈우병 치료 시장 규모는 향후 수년간 안정된 성장이 예상됩니다. 2029년에는 CAGR 4.4%를 나타내 152억 4,000만 달러로 성장할 전망입니다. 예측 기간의 성장은 세계 인구 증가, 헬스케어 투자 증가, 맞춤형 의료의 동향, 국제 공동 연구, 헬스케어 의식의 높아짐, 희귀의약품에 대한 규제 당국의 지원 등에 기인하는 것으로 예측됩니다. 예측 기간의 주요 동향으로는 모니터링·진단기술의 강화, 환자지원 프로그램의 연계, 유전자 치료 접근법의 연구, 면역관용 도입의 이용 확대, 원격진찰을 위한 원격의료 등을 들 수 있습니다.
향후 5년간의 성장률 4.4%라고 하는 예측은 이 시장에 관한 전회의 예측으로부터 0.3%라고 하는 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 장벽은 아일랜드와 벨기에에서 생산되는 응고 인자 농축 제제 및 면역억제제의 비용을 증가시키고, 치료 지연 및 건강 관리 제공업체의 재정적 부담을 초래함으로써 미국 환자 치료를 위험에 빠뜨릴 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
후천성 혈우병 치료 시장 성장이 예상되는 것은 진행중인 임상시험 증가 때문입니다. 인간을 대상으로 한 연구를 포함한 임상시험은 후천성 혈우병의 새로운 치료법의 안전성과 효능을 평가하는 데 중요한 역할을 합니다. 이러한 임상시험은 연구 진전, 환자 결과 개선, 효과적인 치료 개입 확립에 기여합니다. 2023년 10월 기준 ClinicalTrials.gov에 따르면 전 세계적으로 등록된 시험 수는 2022년 43만 7,523건에서 미국 50개 주 모두와 221개국에서 46만 8,457건으로 증가했습니다. 미국에서만 14만 3,613건(전체의 31%), 미국 이외에서는 25만 1,159건(전체의 54%)이 등록되었습니다. 따라서 진행중인 임상시험 수 증가는 후천성 혈우병 치료 시장의 중요한 촉진요인이 되고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 후천성 혈우병 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 후천성 혈우병 치료 시장 : 성장률 분석
세계의 후천성 혈우병 치료 시장 실적 : 규모와 성장(2019-2024년)
세계의 후천성 혈우병 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 후천성 혈우병 치료 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 후천성 혈우병 치료 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
수요 기반
예방 치료
세계의 후천성 혈우병 치료 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
혈우병 A
혈우병 B
혈우병 C
기타 유형
세계의 후천성 혈우병 치료 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
클리닉
기타 최종 사용자
세계의 후천성 혈우병 치료 시장 : 수요 기반 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
응고 인자 대체 요법
데스모프레신
기타 수요 기반 치료법
세계의 후천성 혈우병 치료 시장 : 예방 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
응고 인자 대체 요법
유전자 치료
기타 예방 치료법
제7장 지역별/국가별 분석
세계의 후천성 혈우병 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 후천성 혈우병 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
후천성 혈우병 치료 시장 : 경쟁 구도
후천성 혈우병 치료 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Amgen Inc.
Novo Nordisk A/S
Baxter Healthcare Corporation
Teva Pharmaceutical Industries Ltd.
Mylan NV
Biogen Inc.
CSL Limited
Grifols SA
Genentech Inc.
Octapharma AG
Ferring Pharmaceuticals BV
Shire plc
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
후천성 혈우병 치료 시장(2029년) : 새로운 기회를 제공하는 국가
후천성 혈우병 치료 시장(2029년) : 새로운 기회를 제공하는 부문
후천성 혈우병 치료 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
The treatment of acquired hemophilia refers to therapeutic approaches utilized to manage and address this non-hereditary bleeding disorder. It arises from a mutation or alteration in one of the genes responsible for producing clotting factor proteins crucial for blood clot formation. The treatment involves various strategies, including controlling bleeding episodes and eliminating inhibitors that target clotting factors.
The primary treatments for acquired hemophilia include on-demand and prophylaxis. On-demand treatment involves administering clotting factor replacement therapy only in response to clinically significant bleeding. Hospitals, clinics, and other end users prescribe this treatment for hemophilia A, hemophilia B, hemophilia C, and other related conditions.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The acquired hemophilia treatment market research report is one of a series of new reports from The Business Research Company that provides acquired hemophilia treatment market statistics, including acquired hemophilia treatment industry global market size, regional shares, competitors with an acquired hemophilia treatment market share, detailed acquired hemophilia treatment market segments, market trends and opportunities, and any further data you may need to thrive in the acquired hemophilia treatment industry. This acquired hemophilia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acquired hemophilia treatment market size has grown strongly in recent years. It will grow from $12.2 billion in 2024 to $12.83 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to increasing ageing population, improved diagnostics and awareness, expanding patient pool, collaborative research initiatives, regulatory support and approvals.
The acquired hemophilia treatment market size is expected to see steady growth in the next few years. It will grow to $15.24 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to growing global population, rising healthcare investments, personalized medicine trends, international collaborations in research, increasing healthcare awareness, regulatory support for orphan drugs. Major trends in the forecast period include enhanced monitoring and diagnostic technologies, collaboration for patient support programs, research on gene therapy approaches, increased utilization of immune tolerance induction, telemedicine for remote consultations.
The forecast of 4.4% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade barriers may jeopardize U.S. patient care by inflating the cost of clotting factor concentrates and immunosuppressants produced in Ireland and Belgium, leading to treatment delays and financial strain on healthcare providers. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated growth in the acquired hemophilia treatment market is expected to be driven by an increasing number of ongoing clinical trials. Clinical trials, which involve research studies with human participants, play a crucial role in evaluating the safety and effectiveness of new medical treatments for acquired hemophilia. These trials contribute to advancing research, enhancing patient outcomes, and establishing effective therapeutic interventions. As of October 2023, according to ClinicalTrials.gov, the number of registered studies globally increased from 437,523 in 2022 to 468,457 across all 50 states in the United States and 221 countries. The U.S. alone accounted for 143,613 studies (31% of the total), while non-U.S. locations registered 251,159 studies (54% of the total). Hence, the growing number of ongoing clinical trials is a significant driver for the acquired hemophilia treatment market.
The rising healthcare expenditure is anticipated to drive the growth of the acquired hemophilia treatment market in the future. Healthcare expenditure refers to the total amount of money spent on healthcare goods and services over a specific period, typically expressed in monetary terms. This expenditure is vital for acquired hemophilia treatment as it enables access to advanced therapies, medical interventions, and comprehensive care, ultimately influencing patient outcomes and the overall management of this rare bleeding disorder. For instance, in March 2022, the Centers for Medicare & Medicaid Services, a federal agency in the U.S., published the 2021-2030 National Health Expenditure (NHE) report, indicating that national health spending is projected to grow at an average rate of 5.1% annually between 2021 and 2030, reaching nearly $6.8 trillion. Furthermore, Medicare spending is expected to rise at an annual rate of 7.2%, while Medicaid spending will increase at a rate of 5.6% during the same period. Thus, the growth in healthcare expenditure is propelling the acquired hemophilia treatment market forward.
Major companies in the acquired hemophilia treatment market are actively focused on obtaining approvals for drugs with additional measures to strengthen their market position. Drug approvals that include routine prophylaxis are increasing, addressing the need for more effective and safer treatment options. For instance, in June 2022, Chugai Pharmaceutical received extended approval from Japan's Ministry of Health, Labor and Welfare to expand the use of Hemlibra (emicizumab) for routine prophylaxis in acquired hemophilia A patients, aiming to reduce or minimize the occurrence of bleeds. This bispecific antibody simultaneously targets factor IX and factor X binding sites, enhancing the control of bleeding in patients.
In June 2023, Baudax Bio. completed the acquisition of TeraImmune Inc., an advanced research company based in the U.S., for an undisclosed amount. This strategic move aimed to combine TeraImmune's scientific expertise with Baudax Bio.'s proficiency in executing clinical development programs. The acquisition incorporated TeraImmune's TI-168 asset, a promising next-generation, autologous FVIII TCR-Treg cell therapy candidate designed to neutralize clotting factor VIII (FVIII) inhibitors in Hemophilia A patients. TeraImmune Inc. contributed valuable advancements in the field of treatments for hemophilia.
Major companies operating in the acquired hemophilia treatment market report are Pfizer Inc., Roche Holding AG, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Baxter Healthcare Corporation, Teva Pharmaceutical Industries Ltd., Mylan NV, Biogen Inc., CSL Limited, Grifols SA, Genentech Inc., Octapharma AG, Ferring Pharmaceuticals BV, Shire PLC, BioMarin Pharmaceutical Inc., Sobi Inc., Kedrion Biopharma Inc., Chugai Pharmaceutical Co. Ltd., Spark Therapeutics Inc., Medexus Pharmaceuticals Inc., UniQure NV, Catalyst Biosciences Inc., Hema Biologics LLC, BioXcel Corporation
North America was the largest region in the acquired hemophilia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired hemophilia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the acquired hemophilia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The acquired hemophilia treatment market consists of revenues earned by entities by providing services such as eradication of inhibitors, individualized therapeutic approach, multidisciplinary approach, and prevention services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acquired hemophilia treatment market also includes sales of immunosuppressive agents including cyclosporine A, and azathioprine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acquired Hemophilia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acquired hemophilia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for acquired hemophilia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acquired hemophilia treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Treatment: On-Demand; Prophylaxis
2) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
3) By End User: Hospitals; Clinic; Other End Users
Subsegments:
1) By On-Demand: Clotting Factor Replacement Therapy; Desmopressin; Other On-Demand Treatments
2) By Prophylaxis: Clotting Factor Replacement Therapy; Gene Therapy; Other Prophylaxis Treatments
3. Acquired Hemophilia Treatment Market Trends And Strategies
4. Acquired Hemophilia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Acquired Hemophilia Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Acquired Hemophilia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Acquired Hemophilia Treatment Market Growth Rate Analysis
5.4. Global Acquired Hemophilia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Acquired Hemophilia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Acquired Hemophilia Treatment Total Addressable Market (TAM)
6.1. Global Acquired Hemophilia Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
On-Demand
Prophylaxis
6.2. Global Acquired Hemophilia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hemophilia A
Hemophilia B
Hemophilia C
Other Types
6.3. Global Acquired Hemophilia Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinic
Other End Users
6.4. Global Acquired Hemophilia Treatment Market, Sub-Segmentation Of On-Demand, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clotting Factor Replacement Therapy
Desmopressin
Other On-Demand Treatments
6.5. Global Acquired Hemophilia Treatment Market, Sub-Segmentation Of Prophylaxis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Clotting Factor Replacement Therapy
Gene Therapy
Other Prophylaxis Treatments
7. Acquired Hemophilia Treatment Market Regional And Country Analysis
7.1. Global Acquired Hemophilia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Acquired Hemophilia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
